Responsible use of new antibiotics for critically ill patients suffering from infections due to carbapenem-resistant organisms-a narrative review for an enablement strategy. [PDF]
Eckmann C +16 more
europepmc +1 more source
Spread of carbapenemase-producing <i>Serratia</i> spp. in France from 2016 to 2024: a comparative genomic study. [PDF]
Rezzoug I +8 more
europepmc +1 more source
Current progress in antibacterial agents for carbapenem-resistant enterobacterales. [PDF]
Xu W +10 more
europepmc +1 more source
Classification and applicability of new beta-lactamase inhibitors. [PDF]
Cercenado E, Candel FJ.
europepmc +1 more source
Correction: Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. [PDF]
Frontiers Production Office.
europepmc +1 more source
Carbapenem resistance in a <i>Klebsiella quasipneumoniae</i> isolate resulting from production of CTX-M-33 and OmpK36 porin deficiency. [PDF]
Findlay J +5 more
europepmc +1 more source
Drug-Drug Interactions in Recently Approved Antibacterials: A Mini Review. [PDF]
Baccari I, Bergmann F, Zeitlinger M.
europepmc +1 more source
Preclinical Pharmacokinetics and Pharmacodynamics of Antibiotic Adjuvants. [PDF]
Pham VT +4 more
europepmc +1 more source
Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance. [PDF]
Park SB, Kim MY, Cha SS.
europepmc +1 more source
FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches. [PDF]
Benedetto Tiz D.
europepmc +1 more source

